Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • GBMA Executive and Board
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Historical Event Reporting
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
        • 2020
        • 2021
        • 2022
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • New 5-year Strategic Agreement
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • International Generic and Biosimilar Medicines Association (IGBA)
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2023
    • News 2022
    • News 2021
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Historical Event Reporting

Historical Event Reporting

The Generic and Biosimilar Medicines Association Code of Practice was introduced on 1 March 2010.

Since then, GBMA members have consistently demonstrated ethical conduct in line with community and professional expectations, and in compliance with the principles of the Code.

Recognising that the Code must evolve in parallel with the environment in which its members operate and supported by member’s continued adherence to the Code requirements, educational event and non-price benefit reporting requirement was removed from the 4th edition of the Code, adopted in December 2015.

Historical educational event and non-price benefit reports, 2010 – 2015, can be found by clicking through the hyperlinks provided here.

The Code, now in its 5th edition, effective June 2021, continues to describe expected high standards of conduct for its members, along with an established complaint handling process.

The GBMA believes the Code of Practice is appropriate for self-regulation of suppliers of generic and biosimilar medicines and recognises the unique environment in which its members operate.

Our Members

Sandoz Logo
Sandoz Logo Sandoz Blue RGB
PRIMARY_neo_health_logo_RGB[86]
PRIMARY_neo_health_logo_RGB[86]
logo_ACCORD
logo_ACCORD
Organon logo
Organon logo
Gedeon_Richter_HOR_CMYK-01
Gedeon_Richter_HOR_CMYK-01
Juno
Juno
Teva
Teva
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
CommEyes_Logo_Full (3)
CommEyes_Logo_Full (3)
sinapse
sinapse
PearceIP-Masterbrand-CMYK-tag
PearceIP-Masterbrand-CMYK-tag

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

IGBA’s Annual Global Biosimilars Week Focuses on Oncology Care

November 14, 2023

Tuesday, November 14, 2023 Geneva, Switzerland In the week … More...

Neo Health joins GBMA under new membership tier

September 28, 2023

Thursday, September 28, 2023 Canberra, … More...

GBMA welcomes Teva Pharma to its growing membership base

July 24, 2023

Tuesday July 25, 2023 Canberra, … More…

© 2023 Generic and Biosimilar Medicines Association Pty Ltd | Privacy Policy | Contact Us